REV-ERB agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
== Opinion polls == In 2005 Forschungsgruppe Wahlen researcher Matthias Jung, who was involved in organising opinion polling for the election, spoke of the difficulties of the task. He attributed this to the unpredictable behaviour of the electorate as well as the total lack of infrastructure and methods for gauging public opinion, which forced the institute to build an entirely new polling model. Despite beginning work at the end of 1989, FW only released one poll before the election, which Jung claimed accurately predicted the CDU victory. This may refer to a FW poll showing that 35% of voters believed an Alliance for Germany-led government would be most capable of solving the country's problems, while only 27% believed an SPD-led government would; 29% believed a grand coalition would be most capable. This starkly contrasted with other polls, conducted without reliable methods, which predicted a landslide SPD victory.
===== Electrode ===== In 2010, researchers first reported creating a graphene-silicon heterojunction solar cell, where graphene served as a transparent electrode and introduced a built-in electric field near the interface between the graphene and n-type silicon to help collect charge carriers. In 2012 researchers reported efficiency of 8.6% for a prototype consisting of a silicon wafer coated with trifluoromethanesulfonyl-amide (TFSA) doped graphene. Doping increased efficiency to 9.6% in 2013. In 2015 researchers reported efficiency of 15.6% by choosing the optimal oxide thickness on the silicon. This combination of carbon materials with traditional silicon semiconductors to fabricate solar cells has been a promising field of carbon science. In 2013, another team reported 15.6% percent by combining titanium oxide and graphene as a charge collector and perovskite as a sunlight absorber. The device is manufacturable at temperatures under 150 °C (302 °F) using solution-based deposition. This lowers production costs and offers the potential using flexible plastics. In 2015, researchers developed a prototype cell that used semitransparent perovskite with graphene electrodes. The design allowed light to be absorbed from both sides. It offered efficiency of around 12 percent with estimated production costs of less than $0.06/watt. The graphene was coated with PEDOT:PSS conductive polymer (polythiophene) polystyrene sulfonate). Multilayering graphene via CVD created transparent electrodes reducing sheet resistance.
Adorno rejected the so-called unity of theory and praxis advocated by the students and argued that the students' actions were premised upon a mistaken analysis of the situation. The building of barricades, he wrote to Marcuse, is "ridiculous against those who administer the bomb." Adorno would refer to the radical students as "stormtroopers (Sturmabteilung) in jeans." In September 1968, Adorno went to Vienna for the publication of Alban Berg: Master of the Smallest Link. Upon his return to Frankfurt, events prevented his concentrating upon the book on aesthetics he wished to write: "Valid student claims and dubious actions," he wrote to Marcuse, "are all so mixed up together that all productive work and even sensible thought are scarcely possible any more." After striking, students threatened to strip the Institute's sociology seminar rooms of their furnishings and equipment, and the police were brought in to close the building.
Sources: en.wikipedia.org
==== Kinases ==== Protein kinases are the enzymes responsible for phosphorylation of serine and threonine residues. O-GlcNAc has been identified on over 100 (~20% of the human kinome) kinases, and this modification is often associated with alterations in kinase activity or kinase substrate scope. O-GlcNAc may have diverse functional consequences on kinases such as interfering with ATP binding, altering substrate recognition, or regulating other PTMs on kinases. Complex cross-talk relations can also exist where OGT and a kinase, e.g., AMPK, modify each other.
In 1952, iproniazid, an antimycobacterial agent, was discovered to have psychoactive properties while researched as a possible treatment for tuberculosis. Researchers noted that patients given iproniazid became cheerful, more optimistic, and more physically active. Soon after its development, iproniazid and related substances were shown to slow enzymatic breakdown of serotonin, dopamine, and norepinephrine via inhibition of the enzyme monoamine oxidase. For this reason, this class of drugs became known as monoamine oxidase inhibitors, or MAOIs. During this time development of distinctively different antidepressant agents was also researched. Imipramine became the first clinically useful tricyclic antidepressant (TCA). Imipramine was found to affect numerous neurotransmitter systems and to block the reuptake of norepinephrine and serotonin from the synapse, therefore increasing the levels of these neurotransmitters. Use of MAOIs and TCAs gave major advances in treatment of depression but their use was limited by unpleasant side effects and significant safety and toxicity issues. Throughout the 1960s and 1970s, the catecholamine hypothesis of emotion and its relation to depression was of wide interest and that the decreased levels of certain neurotransmitters, such as norepinephrine, serotonin, and dopamine might play a role in the pathogenesis of depression. This led to the development of fluoxetine, the first SSRI.
== Medical use == Paclitaxel is approved in the UK for ovarian, breast, lung, bladder, prostate, melanoma, esophageal, and other types of solid tumor cancers as well as Kaposi's sarcoma. It is recommended in National Institute for Health and Care Excellence (NICE) guidance of June 2001 for non-small-cell lung cancer in patients unsuitable for curative treatment, and in first-line and second-line treatment of ovarian cancer. In September 2001, NICE recommended paclitaxel for the treatment of advanced breast cancer after the failure of anthracyclic chemotherapy, but that its first-line use should be limited to clinical trials. In September 2006, NICE recommended paclitaxel should not be used in the adjuvant treatment of early node-positive breast cancer. It is approved in the United States for the treatment of breast, pancreatic, ovarian, Kaposi's sarcoma and non-small-cell lung cancers.
Sources: en.wikipedia.org
mid body The centrally constricted region that forms across the central axis of a cell during cytokinesis, constricted by the closing of the contractile ring until the daughter cells are finally separated, but occasionally persisting as a tether between the two cells for as long as a complete cell cycle.
Most polyphenols are metabolized by catechol-O-methyltransferase, and therefore do not have the chemical structure allowing antioxidant activity in vivo; they may exert biological activity as signaling molecules.
=== 18 June === Ukrainian forces retook the village of Tykhe, west of Vovchansk. In Russia, the governor of Rostov Oblast claimed that several oil storage tanks were set on fire by a drone strike in Azov that destroyed 5,000 cubic metres of petroleum products. An oil depot in Krasnodar Krai was struck by Neptune missiles according to local sources, damaging a pipeline, “technical facilities” and starting a fire. No casualties were reported. A Ukrainian court sentenced a resident of Donetsk Oblast to 15 years' imprisonment for spying on Ukrainian positions on behalf of Russia during the Battle of Bakhmut. Swiss authorities claimed to have foiled an assassination attempt aimed at the Ukrainian peace summit, saying that a Russian diplomat was arrested a “few weeks” prior after trying to buy firearms. Ukrainian military observer Kostyantyn Mashovets claimed that the Russian Central Grouping of Forces has about 87,000 personnel, 365 tanks, 864 armored combat vehicles, of which about 68,000-70,000 personnel, 310-320 tanks, and about 576 armored fighting vehicles are currently deployed in the Pokrovsk direction.
=== Maximum depositional age === Some of the most important information we can get from detrital zircon ages is the maximum depositional age of the referring sedimentary unit. The sedimentary unit cannot be older than the youngest age of the analyzed detrital zircons because the zircon should have existed before the rock formation. This provides useful age information to rock strata where fossils are unavailable, such as the terrestrial successions during Precambrian or pre-Devonian times. Practically, maximum depositional age is averaged from a cluster of youngest age data or the peak in age probability because the youngest U-Pb age within a sample is almost always younger with uncertainty.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.